Venlafaxine involves nitric oxide modulatory mechanism in experimental model of chronic behavior despair in mice

Brain Research

Volumn 1311, Issue , 2010, Pages 73-80

  Kumar, Anil ^a   Garg, Ruchika ^a   Gaur, Vaibhav ^a   Kumar, Puneet ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Anxiety; Fatigue syndrome; Locomotor activity; Nitric oxide modulator; Oxidative stress; Venlafaxine

Indexed keywords

ARGININE; CAFFEINE; CATALASE; GLUTATHIONE; METHYLENE BLUE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRITE; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVITY; EXPERIMENTAL MODEL; FORCED SWIMMING TEST; IMMOBILIZATION; LIPID PEROXIDATION; MALE; MAZE TEST; MODULATION; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; ARGININE; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHRONIC DISEASE; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; MALE; METHYLENE BLUE; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; OXIDATIVE STRESS; RANDOM ALLOCATION; SWIMMING;

ANIMALIA; MUS;

EID: 72649099613     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.11.050     Document Type: Article

References (57)

1. Abumaria N., Rygula R., Hiemke C., Fuchs E., Havemann-Reinecke U., Rüther E., and Flügge G. Effect of citalopram on serotonin-related and stress-regulated genes in the dorsal raphe nucleus of the rat. Eur. Neuropsychopharmacol. 17 (2007) 417-429
2. +)-dependent caspase-2 activation induced by oxidative stress leads to SH-SY5Y human neuroblastoma cell apoptosis. J. Neurosci. Res. 68 (2002) 454-462
3. Bilici M., Efe H., Koroglu M.A., Uydu H.A., Bekaroglu M., and Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J. Affect. Disord. 64 (2001) 43-51
4. Chambers D., Bagnall A.M., Hempel S., and Forbes C. Interventions for the treatment, management and rehabilitation of patients with fatigue syndrome/myalgic encephalomyelitis: an updated systematic review. J. R. Soc. Med. 99 (2006) 506-520
5. Contestabile A. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res. Rev. 32 (2003) 476-509
6. Cregan S.P., Fortin A., MacLaurin J.G., Callaghan S.M., Cecconi F., Yu S.W., Dawson T.M., Dawson V.L., Park D.S., Kroemer G., and Slack R.S. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J. Cell Bio. 158 (2002) 507-517
7. Da Silva G., Matteussi A., Santos A.R.S., Calixto J.B., and Rodrigues A.L.S. Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice. NeuroReport 11 (2000) 3699-3702
8. Devanur L.D., and Kerr J.R. Chronic fatigue syndrome. J. Clin. Virol. 37 (2006) 139-150
9. Dhir A., and Kulkarni S.K. Involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. Prog. Neuro-psychopharmacol. Biol. Psychiatry 31 (2007) 921-925
10. Dhir A., and Kulkarni S.K. Venlafaxine reverses chronic fatigue-induced behavioral, biochemical and neurochemical alterations in mice. Pharmacol. Biochem. Behav. 89 (2008) 563-571
11. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82 (1959) 48670-48677
12. Esplugues J.V. NO as a signalling molecule in the nervous system. Br. J. Pharmacol. 135 (2002) 1079-1095
13. Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., and Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study, International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med. 121 (1994) 953-959
14. Gornall A.G., Bardawill C.J., and David M.M. Determination of serum proteins by means of the biuret reaction. J. Biol. Chem. 177 (1949) 751-766
15. Gould G.G., Altamirano A.V., Javors M.A., and Frazer A. A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol. Psychiatry 59 (2006) 408-414
16. Green L.C., Wagner D.A., and Glagowski J. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal. Biochem. 126 (1982) 131-138
17. Gutierrez M.A., Stimmel G.L., and Aiso J.Y. Venlafaxine: a 2003 update. Clin. Ther. 25 (2003) 2138-2154
18. Gyawali K., Pandhi P., and Sharma P.L. Caffeine induced psychomotor behaviour in mice and its antagonism by some drugs. Indian J. Pharmac. 23 (1991) 95-98
19. Harkin A., Connor T.J., Burns M.P., and Kelly J.P. Nitric oxide inhibitors augment the effect of serotonin re-uptake inhibitors in the forced swimming test. Eur. Neuropsychopharmacol. 14 (2004) 274-281
20. Kaster M.P., Santos A.R., and Rodrigues A.L. Involvement of 5-HT1A receptors in the antidepressant-like effect of adenosine in the mouse forced swimming tes. Brain Res. Bull. 67 (2005) 53-61
21. Kaster M.P., Budni J., Santos A.R., and Rodrigues A.L. Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of adenosine in the mouse forced swimming test. Eur. J. Pharmacol. 576 (2007) 91-98
22. Kaur G., and Kulkarni S.K. Comparative study of antidepressants and herbal psychotropic drugs in a mouse model chronic fatigue. J. Chronic Fatigue Syndrome 6 (2000) 23-35
23. Komaroff A.L. The biology of chronic fatigue syndrome. Am. J. Med. 10 (2000) 8169-8171
24. Komaroff A.L., and Buchwald D. Symptoms and signs of chronic fatigue syndrome. Rev. Infect. Dis. 13 (1991) S8-S11
25. Komaroff A.L., Fagioli L.R., and Geiger A.M. An examination of the working case definition of chronic fatigue syndrome. Am. J. Med. 100 (1996) 56-64
26. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat. Med. 3 (1997) 614-620
27. Kulkarni S.K., and Reddy D.S. Animal behavioral models for testing antianxiety agents. Method Find Exp. Clin. Pharmacol. 18 (1996) 219-230
28. Kulkarni S.K., Singh K., and Bishnoi M. Involvement of adenosinergic receptors in anxiety related behaviours. Indian J. Exp. Biol. 45 (2007) 439-443
29. Kumar A., and Garg R. A role of nitric oxide mechanism involved in the protective effects of venlafaxine in sleep deprivation. Behav. Brain Res. 194 (2008) 169-173
30. Kumar P., and Kumar A. Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain. Prog. Neuropsychopharmacol. Biol. Psychiatry 33 (2009) 100-108
31. Kuratsune H., Yamaguti K., Lindh G., Evengard B., Hagberg G., Matsumura K., Iwase M., Onoe H., Takahashi M., Machii T., Kanakura Y., Kitani T., Langstrom B., and Watanabe Y. Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. Neuro Image 17 (2002) 1256-1265
32. Li X.M., Chlan-Fourney J., Juorio A.V., Bennett V.L., Shrikhande S., and Bowen R.C. 1-deprenyl potentiates NGF-induced changes in superoxide dismutase mRNA in PC12 cells. J. Neurosci. Res. 53 (1998) 235-238
33. Luck H. Catalase. In: Bergmeyer H.U. (Ed). Methods of Enzymatic Analysis (1971), Academic Press, New York 885-893
34. Mantovani M., Pertile R., Calixto J.B., Santos A.R., and Rodrigues A.L. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-d-aspartate receptors and the l-arginine-nitric oxide pathway. Neurosci. Lett. 343 (2003) 1-4
35. Mason J.W. A historical view of stress field. J. Hum. Stress 1 (1975) 6-12
36. Ozcan M.E., Gulec M., Ozerol E., Polat R., and Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int. Clin. Psychopharmacol. 19 (2004) 89-95
37. Pall M.L. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med. Hypotheses 54 (2000) 115-125
38. Pall M.L. Nitric oxide synthase partial uncoupling as a key switching mechanism for the NO/ONOO-cycle. Med. Hypotheses 69 (2007) 821-825
39. Papadopoulos M., Koumenis I., Dugan L., and Giffard R. Vulnerability to glucose deprivation injury correlates with glutathione in astrocytes. Brain Res. 748 (1997) 151-156
40. Papanicolaou D.A., Amsterdam J.D., Levine S., McCann S.M., Moore R.C., Newbrand C.H., Allen G., Nisenbaum R., Pfaff D.W., Tsokos G.C., Vgontzas A.N., and Kales A. Neuroendocrine aspects of chronic fatigue syndrome. Neuroimmunomodulation 11 (2004) 65-74
41. Parker A.J., Wessely S., and Cleare A.J. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol. Med. 31 (2001) 1331-1345
42. Radi R., Rodriguez M., Castro L., and Telleri R. Inhibition of mitochondrial electron transport by peroxynitrite. Arch. Biochem. Biophys. 308 (1994) 89-95
43. Redrobe J.P., Bourin M., Colombel M.C., and Baker G.B. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology (Berl) 138 (1998) 1-8
44. Richard R.S., Wang L., and Jelinek H. Erythrocyte oxidative damage in chronic fatigue syndrome. Arch. Med. Res. 38 (2007) 94-98
45. Salome N., Viltart O., Lesage J., Landgraf R., Vieau D., and Laborie C. Altered hypothalamo-pituitary-adrenal and sympatho-adrenomedullary activities in rats bred for high anxiety: central and peripheral correlates. Psychoneuroendocrinology 31 (2006) 724-735
46. Sanders P., and Korf J. Neuroaetiology of chronic fatigue syndrome: an overview. World J. Biol. Psychiatry 8 (2007) 1-7
47. Sharpe M., Hawton K., Clements A., and Cowen P.J. Increased brain serotonin function in men with chronic fatigue syndrome. BMJ (Clin. Res. Ed.) 315 (1997) 164-165
48. Singh A., Naidu P.S., Gupta S., and Kulkarni S.K. Effect of natural and synthetic antioxidants in a mouse model of chronic fatigue syndrome. J. Med. Food 5 (2002) 211-220
49. Soravia L.M., Heinrichs M., Aerni A., Maroni C., Schelling G., Ehlert U., Roozendaal B., and de Quervain D.J. Glucocorticoids reduce phobic fear in humans. Proc. Natl. Acad. Sci. U. S. A. 103 14 (2006) 5585-5590
50. Tanda G., and Goldberg S.R. Alteration of the behavioral effects of nicotine by chronic caffeine exposure. Pharmacol. Biochem. Behav. 66 (2000) 47-64
51. Thomas M.A., and Smith A.P. An investigation of the long-term benefits of antidepressant medication in the recovery of patients with chronic fatigue syndrome. Hum. Psychopharmacol. 21 (2006) 503-509
52. Thome J., Sakai N., Shin K., Steffen C., Zhang Y.J., Impey S., Storm D., and Duman R.S. cAMP response element-mediated gene transcription is up-regulated by chronic antidepressant treatment. J. Neurosci. 20 (2000) 4030-4036
53. Torres R.L., Torresi L.S., Gamaro G.D., Fontella F.U., Silveira P.P., Moreira J.S.R., Lacerda M., Amoretti J.R., Rech D., Dalmaz C., and Bello A.A. Lipid peroxidation and total radical- trapping potential of the lungs of rats submitted to chronic and subchronic stress. Braz. J. Med. Biol. Res. 37 (2004) 185-192
54. Van der Meersch-Mougeot V., da Rocha M., Monier C., Diquet B., Puech A.J., and Thiébot M.H. Benzodiazepines reverse the anti-immobility effect of antidepressants in the forced swimming test in mice. Neuropharmacology 32 (1993) 439-446
55. Warner D.S., Sheng H., and Batinic-Haberele I. Oxidants, antioxidants and the ischemic brain. J. Exp. Biol. 207 (2004) 3221-3231
56. Wills E.D. Mechanism of lipid peroxide formation in animal tissues. Biochem. J. 99 (1966) 667-676
57. Yildiz F., Erden B.F., Ulak G., Utkan Y., and Gacar N. Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology 149 (2000) 41-44